Feature|Articles|May 14, 2024
- Pharmaceutical Executive: May 2024
- Volume 44
- Issue 5
Pharmaceutical Executive: May 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive May 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 1 year ago
'Patients are Waiting'over 1 year ago
Patient Treatment & Travel: The Need for Stepped-Up Supportover 1 year ago
A Biosimilars Roadmap: Understanding Payer Perceptionsover 1 year ago
Avoiding the Digital Age is Hurting Research Effortsover 1 year ago
Biotech’s Road to Recovery Takes a Wobbly Turnover 1 year ago
Yvonne Greenstreet: Answering the CallNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
J.P. Morgan 2026: Pfizer’s Pivot from Covid to Pipeline Execution
2
JP Morgan 2026: Bristol Myers Squibb Focuses on the Next Decade
3
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
4
Pharmaceutical Executive Daily: Johnson & Johnson Continues $55 Billion Manufacturing Investment
5